SS-31 and MOTS-c peptides: separating lab data from TikTok hype

What did @kellyferrobeauty actually say?

Kelly argued that you should take SS-31 before MOTC because "you're fixing the foundation, you're fixing the mitochondria." Her reasoning: starting with MOTC first could "put you in overdrive" and leave you feeling "really depleted, really tired" if your mitochondria are already weak or inflamed. She described SS-31 as reducing oxidative stress and priming the body, while MOTC "teaches your body how to use fuel more efficiently" and helps burn existing stores rather than adding to them. Worth noting: her primary source for this sequencing recommendation was TikTok comments, which she said openly. Credit for the transparency. Less credit for treating comment sections as clinical evidence.

Does the science back this up?

Partially, and only at the most basic mechanistic level. SS-31 (elamipretide) has legitimate preclinical data behind it. MOTC is far murkier. Neither compound has human clinical trial evidence supporting a specific sequencing protocol.

SS-31 is a mitochondria-targeted antioxidant peptide that localizes to the inner mitochondrial membrane and reduces reactive oxygen species (ROS). Szeto et al. (2014, Journal of Cardiovascular Pharmacology) demonstrated cardioprotective effects in animal models through this mechanism. The idea that it reduces oxidative stress at the mitochondrial level is supported by this research, at least in preclinical settings.

MOTC is less well characterized in peer-reviewed literature. It is often described as a mitochondrial-derived peptide involved in metabolic regulation, but robust human data on dosing, sequencing, or safety simply does not exist in published form. The claim that it "teaches your body how to use fuel more efficiently" is a simplification that goes beyond what the available evidence actually shows.

What did they get wrong (or right)?

She got the general biology of SS-31 directionally correct. Mitochondrial dysfunction is associated with increased oxidative stress, and SS-31 does appear to act on that pathway in animal models. That part holds up reasonably well.

What she got wrong: the sequencing advice. There are no human randomized controlled trials, no published clinical protocols, and no peer-reviewed pharmacokinetic data comparing SS-31-first versus MOTC-first sequencing in humans. Deriving a protocol from TikTok comments is not a deep dive, it is a crowd poll. The claim that starting with MOTC could cause fatigue if mitochondria are "weak and inflamed" is biologically plausible in a very loose sense, but it is not established by any study she could cite, because that study does not exist.

The metabolic claims about MOTC, specifically that it helps the body "burn what you already have instead of storing it," edge toward weight-loss adjacent language that the evidence does not support in humans. That framing should be flagged, not amplified.

What should you actually know?

Both SS-31 and MOTC are research-stage compounds. SS-31 (elamipretide) has the stronger scientific foundation of the two, with published preclinical data and some early human trials for specific conditions like Barth syndrome and heart failure. Sabbah et al. (2016, JACC: Basic to Translational Science) showed improvements in mitochondrial function in heart failure models, but this is a far cry from a general wellness protocol.

MOTC's human evidence base is thin. Posting a peptide sequencing protocol derived from comment sections, regardless of how confident it sounds, is not the same as evidence-based guidance. Anyone considering either compound should consult a licensed clinician familiar with peptide pharmacology, not a comment thread. These are not supplements. They are not FDA-approved for general use. The gap between "biologically interesting" and "clinically validated protocol" is significant, and this video does not acknowledge that gap at all.